Finally, in the context of IDH-wild-type glioma, the evidence of a pTERT mutation is sufficient to retain the diagnosis of IDH-wild-type glioblastoma grade IV even in the absence of microvascular proliferation or necrosis according to the recommendations of the c-IMPACT-NOW group (21). This evidence concerns the gene IDH1 and glioblastoma.